MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders
Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA.
Free plan · Plus CA$29 or Pro CA$99/month


